The 2-week wait pathway for suspected head and neck cancers in patients with throat and voice symptoms: referral patterns, common clinical practice and diagnostic efficacy of NICE guidelines.

Autor:	Chiumenti FA; University College London Hospitals NHS Foundation Trust, UK., Pendolino AL; University College London Hospitals NHS Foundation Trust, UK.; UCL Ear Institute, UK., Vaz FM; University College London Hospitals NHS Foundation Trust, UK.; Christchurch Canterbury University, UK., Dwivedi RC; University College London Hospitals NHS Foundation Trust, UK.; University College London, UK.
Jazyk:	angličtina
Zdroj:	Annals of the Royal College of Surgeons of England [Ann R Coll Surg Engl] 2024 Nov 12. Date of Electronic Publication: 2024 Nov 12.
DOI:	10.1308/rcsann.2024.0072
Abstrakt:	Introduction: The 2-week wait (2ww) referral pathway has been introduced into UK clinical practice to increase the early detection of cancer and improve survivals. The efficiency of this system for head and neck (H&N) cancers has been questioned over the years because of evidence of low pick-up rates. H&N cancers present with a wide variety of non-specific symptoms, particularly throat and voice symptoms. These symptoms need to be accurately interpreted together with risk factors if they are to be addressed adequately and overload of cancer facilities avoided. One of the most common outcomes of H&N 2ww referrals is laryngopharyngeal reflux (LPR), a common condition that could be diagnosed and managed in the primary care setting with a prescription of proton pump inhibitors (PPI) trials. Methods: We retrospectively analysed a cohort of consecutive patients referred on the 2ww pathway for throat and voice symptoms at University College London Hospital H&N cancer clinic during two months in 2019. Results: A total of 101 patients (43.6% men, mean age 53.3 years) were included. Throat and voice symptoms were described as intermittent in 52.5% and non-lateralised in 88.1%. Diagnosis of LPR was made in 59.4% of the referrals. A PPI trial was prescribed by general practitioners (GPs) in only 7.9% of cases. The cancer pick-up rate in our cohort is 2.9%. Conclusions: An improved awareness of the symptoms of LPR could guide GPs to prescribe trials of PPIs in low-risk patients before rushing into a referral on a cancer pathway. This would improve the 2ww process on many levels, reduce the burden on the National Health Service and avoid patients' psychological distress.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu